Table 2.
Clinical characteristics and CT parameters in the training cohort and validation cohort
| Variable | Total (n = 186) | Training cohort (n = 131) | Validation cohort (n = 55) | P |
|---|---|---|---|---|
| Baseline characteristics of the patients | ||||
| Age(mean [SD], year) | 66 ± 11 | 66.57 ± 11 | 64 ± 10 | 0.322 |
| BMI (median [IQR], kg/m²) | 23.35 (21.63–25.48) | 23.44 (21.50–25.59) | 23.18 (21.97–25.20) | 0.847 |
| Gender, n (%) | 0.772 | |||
| Female | 74 (39.78) | 53 (40.46) | 21 (38.18) | |
| Male | 112 (60.22) | 78 (59.54) | 34 (61.82) | |
| ASA, n (%) | 0.726 | |||
| 1 | 22 (11.83) | 17 (12.98) | 5 (9.09) | |
| 2 | 114 (61.29) | 80 (61.07) | 34 (61.82) | |
| 3 | 50 (26.88) | 34 (25.95) | 16 (29.09) | |
| Hypertension, n (%) | 0.863 | |||
| No | 110 (59.14) | 78 (59.54) | 32 (58.18) | |
| Yes | 76 (40.86) | 53 (40.46) | 23 (41.82) | |
| Diabetes, n (%) | 0.157 | |||
| No | 165 (88.71) | 119 (90.84) | 46 (83.64) | |
| Yes | 21 (11.29) | 12 (9.16) | 9 (16.36) | |
| CT measurement parameters | ||||
| SAT area(mean [SD], cm2) | 127.55 ± 55.04 | 128.57 ± 59.40 | 125.13 ± 43.29 | 0.699 |
| SAT Radiodensity(mean [SD], U) | -97.34 ± 9.03 | -96.95 ± 8.73 | -98.27 ± 7.10 | 0.367 |
| VAT Radiodensity( mean [SD], U) | -94.08 ± 8.36 | -94.18 ± 8.57 | -93.83 ± 7.89 | 0.793 |
| Distance between tumor and the dentate line, n (%) | 0.053 | |||
| < 10cm | 98 (52.69) | 63 (48.09) | 35 (63.64) | |
| ≥ 10 cm | 88 (47.31) | 68 (51.91) | 20 (36.36) | |
| Tumor diameter, n (%) | 0.355 | |||
| ≤ 3 cm | 85 (45.7) | 57 (43.51) | 28 (50.91) | |
| >3 cm | 101 (54.3) | 74 (56.49) | 27 (49.09) | |
| Pathological stage | ||||
| Pathological T stage, n (%) | 0.982 | |||
| T1 | 132 (70.97) | 93 (70.99) | 39 (70.91) | |
| T2 | 43 (23.12) | 30 (22.90) | 13 (23.64) | |
| T3 | 11 (5.91) | 8 (6.11) | 3 (5.45) | |
| Pathological N stage, n (%) | 0.195 | |||
| N0 | 112 (60.22) | 75 (57.25) | 37 (67.27) | |
| N1 | 39 (20.97) | 27 (20.61) | 12 (21.82) | |
| N2 | 35 (18.82) | 29 (22.14) | 6 (10.91) | |
| Nerve invasion, n (%) | 0.396 | |||
| No | 146 (78.49) | 105 (80.15) | 41 (74.55) | |
| Yes | 40 (21.51) | 26 (19.85) | 14 (25.45) | |
| Vascular tumor emboli, n (%) | 0.661 | |||
| No | 152 (81.72) | 106 (80.92) | 46 (83.64) | |
| Yes | 34 (18.28) | 25 (19.08) | 9 (16.36) | |
| Blood Laboratory indicators | ||||
| Preoperative total cholesterol (median [IQR]) | 4.63 (4.24–5.20) | 4.59 (4.17–5.11) | 4.65 (4.30–5.23) | 0.381 |
| Preoperative triglyceride(median [IQR]) | 1.18 (0.95–1.45) | 1.23 (1.01–1.46) | 1.09 (0.71–1.38) | 0.021 |
| Preoperative C reactive protein count(median [IQR]) | 5.20 (4.70–5.70) | 5.10 (4.70–5.70) | 5.50 (4.90–5.70) | 0.058 |
| Preoperative serum albumin, n (%) | 0.854 | |||
| <35 g/L | 39 (20.97) | 27 (20.61) | 12 (21.82) | |
| ≥ 35 g/L | 147 (79.03) | 104 (79.39) | 43 (78.18) | |
| Preoperative hemoglobin (mean [SD]) | 129.78 ± 17.67 | 128.90 ± 16.78 | 131.87 ± 19.63 | 0.296 |
| SIG, n (%) | 0.22 | |||
| 0 | 121 (65.05) | 87 (66.41) | 34 (61.82) | |
| 1 | 46 (24.73) | 31 (23.66) | 15 (27.27) | |
| 2 | 13 (6.99) | 7 (5.34) | 6 (10.91) | |
| 3 | 6 (3.23) | 6 (4.58) | 0 (0.00) | |
BMI body mass index; ASA American Society of Anesthesiologists; SAT subcutaneous fatty tissue; VAT visceral adipose tissue; SIG Systemic Inflammatory Grade